NOVEL IMMUNOTHERAPIES (CAR-T, BiTE)

Results from a recent study of 145 adult patients receiving CAR T-cell therapy demonstrated that this patient population is at an increased risk of experiencing major adverse cardiovascular events (MACEs). Thirty-one patients experienced 41 MACEs at a median 11 days post-CAR T-cell therapy, and cytokine release syndrome occurred 176 times in 104 patients, with a median time to CRS of 6 days (interquartile range: 1 to 8 days).